Literature DB >> 20205056

Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.

Eric E Walk1.   

Abstract

The field of diagnostics has unprecedented opportunities to contribute to the practice of medicine in the era of targeted therapy and personalized healthcare. Rather than simply providing information regarding the presence and classification of disease, innovative molecular diagnostic tests will directly inform patient-management decisions, such as which targeted therapies to prescribe or whether a patient should be treated more aggressively. However, in order for diagnostics to deliver this high level of medical value, several challenges ranging from technical, pre-analytical, developmental, regulatory, reimbursement and quality perspectives need to be overcome. This review focuses on recent developments in each of these areas that are expected to improve the power and impact of diagnostics.

Entities:  

Mesh:

Year:  2010        PMID: 20205056

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  3 in total

1.  Pharmacogenomics in clinical practice: reality and expectations.

Authors:  C Lee Ventola
Journal:  P T       Date:  2011-07

2.  Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy.

Authors:  Muharrem Akcan; Mark R Stroud; Stacey J Hansen; Richard J Clark; Norelle L Daly; David J Craik; James M Olson
Journal:  J Med Chem       Date:  2011-01-06       Impact factor: 7.446

Review 3.  Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies.

Authors:  Luc Bissonnette; Michel G Bergeron
Journal:  J Pers Med       Date:  2012-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.